Post-Influenza Vaccine Palpable Nodules
The palpable nodules appearing after influenza vaccination are most likely reactive lymphadenopathy (if in the axilla/supraclavicular region) or subcutaneous nodules at the injection site, both representing benign immune responses to vaccination. The next step depends on the nodule location and patient cancer risk: for low-risk patients, observation with reassurance is appropriate; for patients with cancer or high metastatic risk, consider short-interval ultrasound follow-up at 6 weeks or tissue biopsy if immediate histopathologic confirmation is needed 1.
Cause: Two Distinct Entities
Regional Lymphadenopathy (Axilla/Supraclavicular)
- Mechanism: Locally activated antigens accumulate at the deltoid injection site and migrate to draining lymph nodes 1
- Frequency: Occurs in up to one-third of cases with conventional vaccines 1
- Timing: Typically manifests within 2-4 days post-vaccination 1
- Location: Axilla and supraclavicular regions ipsilateral to injection site 1
- Duration: Most resolve by 6-12 weeks, though some persist longer 1
Subcutaneous Nodules at Injection Site
- Mechanism: Cutaneous lymphoid hyperplasia in reaction to vaccine components, particularly aluminum-containing vaccines 2, 3
- Timing: Can appear within 3 days but may present as delayed-onset nodules (6-18 months post-vaccination) 2, 3
- Location: Upper arm or thigh at injection site 2, 3
- Duration: 34% resolve by 6 months, 68% by 12 months, but 24% persist >24 months 3
- Associated features: Pruritus in 41% of cases 3
- Recent evidence: A 2025 multicenter study found increased risk of subcutaneous nodules (HR 1.32) and lipomas (HR 1.57) in the upper arm following intramuscular influenza vaccination 4
Next Steps: Risk-Stratified Approach
For Patients WITHOUT Cancer or Low Metastatic Risk
Observation and reassurance is the mainstay of management 2, 3:
- Document vaccination details: date, injection site, laterality, vaccine type 1
- Explain this is a benign, expected immune response
- No routine follow-up imaging required 1
- Reassure that most nodules resolve spontaneously within 6-12 months 3
For Patients WITH Cancer or High Metastatic Risk
Risk assessment determines management intensity 1:
Low nodal metastatic risk (considering cancer type, location, stage):
- Expectant management without default follow-up imaging 1
Higher nodal metastatic risk (breast cancer, head/neck cancers, upper extremity/trunk melanoma, lymphoma):
- Short-interval ultrasound follow-up at ≥6 weeks post-vaccination 1
- This allows reactive adenopathy to resolve before imaging 1
High nodal metastatic risk requiring immediate management:
- Tissue biopsy when immediate histopathologic confirmation is necessary for timely treatment decisions 1
- Consider multidisciplinary discussion in uncertain cases 1
Critical Pitfalls to Avoid
Do NOT delay clinically indicated imaging for acute symptoms, treatment monitoring, urgent treatment planning, or complications due to recent vaccination 1
Do NOT assume all post-vaccine nodules are benign: While rare, vaccination may unmask underlying lymphoproliferative disorders 5. Maintain clinical vigilance for atypical features.
Do NOT perform unnecessary biopsies in low-risk patients with typical presentation and timing 2, 3
Ensure proper documentation: Always obtain and record vaccination history (dates, sites, laterality, vaccine type) before interpreting any nodules 1
Consider alternative diagnoses if presentation is atypical: persistent growth beyond expected timeframe, systemic symptoms, or features inconsistent with reactive changes 2, 3
Special Considerations
- Ultrasound can aid diagnosis when uncertainty exists, showing characteristic features of post-vaccination nodules 6
- Histopathology (when performed) typically shows cutaneous lymphoid hyperplasia 2
- Recurrence is uncommon: Only 1 case in 41 had recurrence with subsequent immunization in one series 3
- Does not contraindicate future vaccination: 83% of patients with prior nodules were fully immunized at follow-up 3